A detailed analysis of T-cell redirecting therapies in oncology, comparing the mechanisms of bispecific antibodies and CAR T ...

An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...

Life sciences researchers need a host of tools to develop and test critical disease-treating drugs and therapies, from basic research to final product release. Primary cells, media, and reagents are ...

An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.

An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests ...

Using Implementation Science Frameworks to Guide the Use of Electronic Patient-Reported Outcome Symptom Monitoring in Routine Cancer Care This was a prospective study in patients undergoing evaluation ...

Most neurons that die in Alzheimer’s disease do not simply starve or get smothered by amyloid plaques. According to a study ...

Phase I clinical trial results suggest that an antibody treatment, used in combination with other drugs, enabled stem cell transplants for three children with Fanconi anemia without toxic busulfan ...

Lung toxicity and fibrosis are caused by inhaling particles, pathogens, and therapeutics. They can also occur following repeated administration of systemic and oral drugs. Any epithelial damage or ...